| abstract |
Disclosed are 2-methylene-1a,25-dihydroxy-18,19,21-trinorvitamin D3 compounds as represented by the general formula I, wherein X1 and X2 are independently selected from H and hydroxy protecting groups. Further disclosed is a pharmaceutical composition which comprises an effective amount of a compound as defined above for the treatment of a biological condition selected from metabolic bone disease; psoriasis; leukaemia; colon cancer; breast cancer; prostate cancer; skin cancer; lung cancer; multiple sclerosis; lupus; diabetes mellitus; host versus graft reaction; rejection of organ transplants; an inflammatory disease selected from rheumatoid arthritis, psoriatic arthritis, asthma, or inflammatory bowel diseases; a skin condition selected from wrinkles, lack of adequate skin firmness, lack of adequate dermal hydration, or insufficient sebum secretion; renal osteodystrophy; osteopenia; vitamin D-resistant rickets or osteoporosis. |